Nevro Corp
NYSE:NVRO
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Nevro Corp
NYSE:NVRO
|
220.9m USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
202.2B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
178.4B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
148B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
124.9B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
113.5B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
47.8B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
52.7B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
50.3B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
50.3B USD |
Loading...
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
38.3B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Nevro Corp
Glance View
Nevro Corp. engages in the provision of medical devices. The company is headquartered in Redwood City, California and currently employs 945 full-time employees. The company went IPO on 2014-11-06. The firm has developed and commercialized the Senza spinal cord stimulation (SCS) system. SCS is a neuromodulation platform for the treatment of chronic pain, with the Senza Omnia platform, which is in addition to the Senza family of products. The Company’s solution for chronic pain includes 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain based on what it believes to be the best clinical evidence available. The advantages of its 10 kHz Therapy over traditional SCS include demonstrated superior efficacy data for both leg and back pain, paresthesia free pain relief for patients, anatomical lead placement for physicians, and ability to treat a broader group of chronic pain patients.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Nevro Corp is 66.4%, which is below its 3-year median of 67.8%.
Over the last 3 years, Nevro Corp’s Gross Margin has decreased from 68.8% to 66.4%. During this period, it reached a low of 66.4% on Jan 1, 2025 and a high of 68.9% on Mar 31, 2024.
